The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data•
Capsugel Lonza — A Better Way to Deliver Microbiome-Based Therapies

Latest in the News

All News →
GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions
 CLINICAL & MANUFACTURING

GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions

Microviable Therapeutics’ GutAlive® kit collects a complete fecal sample and keeps its bacteria alive and anaerobic for up to 120 hours — a different approach to microbiome sampling than DNA-stabilising buffer kits.

BY Microbiome Times · SEP 11, 2026 · 6 MIN READ
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics
CLINICAL & MANUFACTURING

From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics

SEP 4, 2026
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
EDITOR'S CHOICE

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
EDITOR'S CHOICE

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026
Breathing Engineered Bacteria: A New Approach to Treating Lung Disease
GMO & SYNBIO

Breathing Engineered Bacteria: A New Approach to Treating Lung Disease

AUG 10, 2026
Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data
CLINICAL & MANUFACTURING

Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data

AUG 7, 2026
Evonik EUDRACAP colon - GMP quality targeted drug delivery from the upper small intestine to the ileo-colonic region

Editor's Choice

All Editor's Choice →
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
 Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

Caelus welcomes the publication by the European Food Safety Authority (EFSA) of its scientific opinion on the safety of gut bacterium Anaerobutyricum soehngenii CH106 (A. soehngenii) for use in food

BY Microbiome Times · SEP 1, 2026 · 3 MIN READ
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026
LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
Editor's Choice

LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis

MAY 1, 2026